NYSE - Delayed Quote • USD
Compare
At close: 6 September at 4:00 pm GMT-4
After hours: 6 September at 7:52 pm GMT-4
Line
Candle
Baseline
Mountain
Bar
Loading Chart for JNJ
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous close
164.99 - Open
165.18 - Bid 164.03 x 1000
- Ask 164.40 x 800
- Day's range
164.12 - 165.94 - 52-week range
143.13 - 168.85 - Volume
3,350,705 - Avg. Volume
6,884,391 - Market cap (intra-day)
395.702B - Beta (5Y monthly) 0.52
- PE ratio (TTM)
24.87 - EPS (TTM)
6.61 - Earnings date 15 Oct 2024
- Forward dividend & yield 4.96 (3.02%)
- Ex-dividend date 27 Aug 2024
- 1y target est
171.83
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
131,900
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Drug Manufacturers - General
Industry
Recent news: JNJ
View moreAll SEC filings
Corporate changes and voting matters
Periodic financial reports
Proxy statements
Tender offer/acquisition reports
Offering registrations
Performance overview: JNJ
Trailing total returns as of 06/09/2024, which may include dividends or other distributions. Benchmark is
YTD return
JNJ
7.33%
S&P 500
13.39%
1-year return
JNJ
5.54%
S&P 500
20.27%
3-year return
JNJ
2.30%
S&P 500
19.25%
5-year return
JNJ
46.70%
S&P 500
81.73%
Compare to: JNJ
Compare
Select to analyse similar companies using key performance metrics; select up to four stocks.
164.38
-0.37%
Mkt cap 395.702B
Industry Drug Manufacturers—General
28.56
+0.18%
Mkt cap 161.841B
Industry Drug Manufacturers—General
117.84
-0.63%
Mkt cap 298.702B
Industry Drug Manufacturers—General
193.40
+0.28%
Mkt cap 341.61B
Industry Drug Manufacturers—General
48.70
-2.21%
Mkt cap 98.734B
Industry Drug Manufacturers—General
902.71
-1.10%
Mkt cap 812.824B
Industry Drug Manufacturers—General
320.56
-1.17%
Mkt cap 172.246B
Industry Drug Manufacturers—General
78.72
-0.06%
Mkt cap 98.006B
Industry Drug Manufacturers—General
83.05
+0.06%
Mkt cap 257.502B
Industry Drug Manufacturers—General
43.67
+1.25%
Mkt cap 89.064B
Industry Drug Manufacturers—General
116.65
+0.14%
Mkt cap 236.543B
Industry Drug Manufacturers—General
Statistics: JNJ
View more
Valuation measures
As of 06/09/2024
Market cap
395.70B
Enterprise value
411.72B
Trailing P/E
24.87
Forward P/E
15.13
PEG ratio (5-yr expected)
0.96
Price/sales (ttm)
4.67
Price/book (mrq)
5.53
Enterprise value/revenue
4.76
Enterprise value/EBITDA
14.95
Financial highlights
Profitability and income statement
Profit margin
43.91%
Return on assets (ttm)
8.10%
Return on equity (ttm)
22.15%
Revenue (ttm)
86.58B
Net income avi to common (ttm)
16.38B
Diluted EPS (ttm)
6.61
Balance sheet and cash flow
Total cash (mrq)
25.48B
Total debt/equity (mrq)
58.00%
Levered free cash flow (ttm)
19.14B
Research analysis: JNJ
View morePeople also watch
PG The Procter & Gamble Company
175.59
+0.07%
PFE Pfizer Inc.
28.56
+0.18%
MRK Merck & Co., Inc.
117.84
-0.63%
KO The Coca-Cola Company
71.14
-0.04%
WMT Walmart Inc.
76.64
-0.42%
XOM Exxon Mobil Corporation
112.64
-0.47%
MMM 3M Company
128.60
-2.13%
PEP PepsiCo, Inc.
177.34
-0.34%
CVX Chevron Corporation
138.56
-1.68%
VZ Verizon Communications Inc.
41.15
-0.39%
HD The Home Depot, Inc.
360.05
-0.50%
JPM JPMorgan Chase & Co.
212.46
-2.38%
DIS The Walt Disney Company
87.94
-0.80%
IBM International Business Machines Corporation
200.74
-0.91%
ABT Abbott Laboratories
113.86
+0.67%
MCD McDonald's Corporation
289.51
+0.53%